ArticleJournal of pharmaceutical policy and practice2026
Integrated AHP-Delphi and Mini-HTA for selection of metabolic drugs in China's national medical insurance catalog: a framework towards quantitative dynamic adjustment.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: China's high burden of metabolic disease requires more systematic approaches to selecting medicines for inclusion in the National Medical Insurance Catalog. Existing processes face difficulties in quantitatively balancing clinical value, target population needs, pharmacoeconomic evidence, and resource constraints, and may therefore rely heavily on subjective judgment. Methods: We developed a decision framework integrating the analytic hierarchy process (AHP), the Delphi method, and mini-health technology assessment (mini-HTA) principles. Candidate criteria were identified from the WHO Essential Medicines List, India's National List of Essential Medicines, the Kenya Essential Medicines List, China's National Medical Insurance Catalog, and relevant policy-oriented literature on drug selection in China. These criteria were used to construct a systematic and locally adapted framework. Three rounds of consultation were conducted with a multidisciplinary expert panel comprising one clinician, three pharmacists, and three health insurance administrators. Indicator weights were calculated using the geometric mean method. Expert agreement and judgment consistency were assessed using Kendall's coefficient of concordance (W) and consistency ratios (CR), respectively. Results: The framework included 14 primary indicators and 42 secondary indicators. Expert consensus was statistically significant (Kendall's W = 0.57, p < 0.001), and all consistency ratios were below 0.1, indicating acceptable consistency and robustness in weight allocation. Conclusions: The proposed AHP-Delphi-mini-HTA framework provides a quantitative and transparent approach to selecting metabolic drugs for insurance coverage in China. Although prospective pilot testing is still required, the framework supports standardized assessment, reduces reliance on subjective judgment, and may facilitate future integration of real-world evidence and AI-assisted decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.